Welcome to our dedicated page for AVIENT SEC filings (Ticker: AVNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AVIENT's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AVIENT's regulatory disclosures and financial reporting.
Avient Corp director Richard H. Fearon received a grant of 1,049 shares of Avient common stock at no cost. This award increased his direct holdings to 149,115 common shares following the transaction. The filing classifies the transaction as a grant, award, or other acquisition of non‑derivative common stock.
LIN SANDRA BEACH reported acquisition or exercise transactions in this Form 4 filing.
Avient Corporation director Sandra Beach Lin reported updated share holdings and a new equity grant. She received a grant of 1,049 shares of common stock at no cost, bringing her directly held stake to 12,172.723 shares. She also indirectly holds 47,388.785 shares through the Avient Corporation Deferred Compensation Plan for Non-Employee Directors, which includes shares accumulated via a dividend reinvestment feature.
AVIENT CORP director Robert E. Abernathy received a grant of 1,049 shares of Common Stock on June 30, 2026. The shares were acquired at a stated price of $0.00 per share, reflecting a share award rather than an open-market purchase. Following this grant, Abernathy directly holds 41,920 shares of Avient common stock.
Di Salvo Giuseppe reported acquisition or exercise transactions in this Form 4 filing.
Avient Corp reported that SVP and Chief Financial Officer Giuseppe Di Salvo received a grant of 6,357 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Avient common stock, giving him 6,357 RSUs directly following this compensation award.
Avient Corp SVP and CFO Giuseppe Di Salvo filed an initial ownership report showing existing equity interests, without reporting any new purchases or sales. He indirectly holds 18,300.401 shares of Avient common stock through a Supplemental Plan as of June 1, 2026.
He also holds several Stock Appreciation Rights on Avient common stock with exercise prices between $31.48 and $52.64 per share and expiration dates from 2029 through 2034. In addition, he has multiple restricted stock unit awards that each represent a contingent right to receive one share of Avient common stock, vesting between 2027 and 2029 under their grant agreements.
Avient Corporation reported the results of its Annual Meeting of Shareholders held on May 14, 2026. All eleven director nominees were elected, each receiving over 82.9 million votes in favor, with broker non-votes of 1,998,081 for each nominee.
Shareholders also approved, on an advisory basis, the company’s named executive officer compensation, with 80,935,972 votes for, 4,446,644 against, 75,822 abstentions, and 1,998,081 broker non-votes. In addition, shareholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 86,049,990 votes for, 1,363,441 against, and 43,088 abstentions.
Avient Corporation reported a solid turnaround for the quarter ended March 31, 2026. Sales rose to $847.4 million from $826.6 million, while gross margin edged up to 32.2% as productivity and restructuring savings more than offset higher costs.
Operating income jumped to $95.8 million from $0.7 million, mainly because last year’s period included a large impairment tied to the S/4HANA ERP project that was discontinued in 2025. Net income attributable to common shareholders improved to $55.7 million, or $0.61 per diluted share, compared with a loss of $20.2 million, or $(0.22) per share, as lower interest expense and steadier segment performance supported results. The company ended the quarter with $427.6 million in cash, $1,924.5 million of net debt and total liquidity of $917.9 million.
Avient Corporation reported stronger results for the first quarter of 2026, returning to solid profitability and modest sales growth. Sales rose 3% to $847.4 million, helped by a 5% favorable foreign exchange impact. GAAP earnings per share were $0.61, a sharp turnaround from a loss of ($0.22) a year earlier, including $0.06 of special items and $0.16 of intangible amortization.
Adjusted EPS increased 9% to $0.83, slightly above guidance of $0.81, and adjusted EBITDA reached $149.9 million with margins improving to 17.7%. Management expects second quarter adjusted EPS of $0.89, representing 11% year-over-year growth, and reaffirmed full-year 2026 guidance for adjusted EBITDA of $555–$585 million and adjusted EPS of $2.93–$3.17, while noting uncertainty in the second half of the year.
Avient Corp: Schedule 13G showing institutional ownership. Vanguard Capital Management reported beneficial ownership of 4,812,578 shares of Avient Corp common stock, representing 5.24% of the class as of 03/31/2026. The filing lists sole dispositive power over 4,812,578 shares and sole voting power for 696,565 shares. The Schedule 13G was signed on 04/29/2026.
Avient Corp reports that Vanguard Portfolio Management beneficially owns 5,539,975 shares of Common Stock (6.04%). The filing states Vanguard has sole dispositive power over 5,539,975 shares and sole voting power over 37,362 shares. The filing is a Schedule 13G disclosure.